Imaging of a Metastatic Gastrointestinal Carcinoid by F-18-DOPA Positron Emission Tomography

S. Hoegerle; B. Schneider; A. Kraft; E. Moser; E. U. Nitzsche

doi:10.1055/s-0038-1632205

Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 1999; 38(04): 127-130
DOI: 10.1055/s-0038-1632205

Originalarbeiten — Original Articles

Schattauer GmbH

Imaging of a Metastatic Gastrointestinal Carcinoid by F-18-DOPA Positron Emission Tomography

Bildgebende Diagnostik eines metastasierten gastrointestinalen Karzinoids mittels F-18-DOPA-Positronen-Emissions-Tomographie

S. Hoegerle

¹Divisions of Nuclear Medicine and

,

B. Schneider

²Diagnostic Radiology, Department of Radiological Science, and

,

A. Kraft

³Division of Hematology and Oncology, Department of Internal Medicine, Albert Ludwigs University, School of Medicine, Freiburg, Germany

,

E. Moser

¹Divisions of Nuclear Medicine and

,

E. U. Nitzsche

¹Divisions of Nuclear Medicine and

› Institutsangaben

Abstract

Summary

The localization of carcinoids in the gastrointestinal tract is frequently difficult if not impossible with the imaging procedures used to date. It is reported on a patient with metastasizing carcinoid in whom various imaging procedures were not successful in detecting the primary tumor. Due to the importance of primary tumor proof for potential curative surgical therapy, a whole-body positron emission tomography with F-18-DOPA was performed. PET enabled localization of a potential primary tumor in the ileum. Moreover, in addition to the known abdominal lymph node and liver metastases, it detected a mediastinal lymph node metastasis and a pulmonary metastasis. F-18-DOPA whole-body PET may be a very promising imaging approach to the localization and staging of gastrointestinal carcinoids.

Zusammenfassung

Die Lokalisation gastrointestinaler Karzinoide ist mit den existierenden bildgebenden Verfahren nicht selten schwierig oder unmöglich. Es wird über einen Patienten mit metastasierendem gastrointestinalen Karzinoid berichtet, bei dem die üblichen bildgebenden Verfahren keine Lokalisation des Primärtumors ermöglichten. Aufgrund der Bedeutung der Primärtumorkenntnis für einen eventuellen, potentiell kurativen chirurgischen Therapieansatz wurde eine F-18-DOPA-Ganzkörper-Positronen-Emissions-Tomographie durchgeführt. Dieses Verfahren ermöglichte die Lokalisation eines potentiellen Primärtumors im Ileum. Darüber hinaus wurden neben den bekannten abdominellen Lymphknoten- und Lebermetastasen weitere Tumormanifestationen in Form einer mediastinalen Lymphknotenmetastase und einer pulmonalen Filia dargestellt. Somit ist die F-18-DOPA-Ganzkörper-PET ein vielversprechender Ansatz zur Lokalisation und zum Staging gastrointestinaler Karzinoide.

Key words

Carcinoid - F-18-DOPA - positron emission tomography

Schlüsselwörter

Karzinoid - F-18-DOPA - Positronen-Emissions-Tomographie

Volltext

Referenzen

REFERENCES
1 Luxen A, Perlmutter M, Bida GT. et al Remote, semiautomated production of 6-[F-18]fluoro-L-dopa for human studies with PET. J Appl Radiat Isot 1990; 41: 275-81.
2 Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Transactions on Medical Imaging 1994; MI13: 601-9.
3 Debas HT, Orloff SL. Carcinoid Tumors and the Carcinoid Syndrome. In: Sabiston DC. ed. Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 14th ed.. Philadelphia: Saunders; 1991: 869-73.
4 Vinik AI, Mc Leod MK, Fig LM, Shapiro B, Lloyd RV, Cho K. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18: 865-96.
5 Laurent F, Raynaud M, Biset JM, Boisserie-Lacroix M, Grelet P, Drouillard J. Diagnosis and categorization of small bowel neoplasms: role of computed tomography. Gastrointest Radiol 1991; 16: 115-9.
6 Feldman JM, Blinder RA, Lucas KJ, Coleman RE. Iodine 131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med 1986; 27: 1691-6.
7 Hoefnagel CA, den Hartog Jager FCA, Taal BG, Abeling NGGM, Engelsman EE. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987; 13: 187-91.
8 Krenning EP, Bakker WH, Breeman WAP. et al. Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989; I: 242-44.
9 Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993; 20: 283-92.
10 Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin receptor scintigraphy in medullary thyroid cancer and in GEP and carcinoid tumours. Nuklearmedizin 1995; 34: 1-7.
11 Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21: 561-81.
12 Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X. Comparison of somatostatin analogue and metaiodbenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 1996; 23: 1448-54.
13 Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluordeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
14 Rege SD, Höh CK, Glaspy JA. et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluordeoxyglucose. Cancer 1993; 72: 82-90.
15 Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993; 2: 189-96.
16 Ahlström H, Eriksson B, Bergström M, Bjurling P, Langström B, Öberg K. Pancreatic neuroendocrine tumors: diagnosis with, PET. Radiology 1995; 195: 333-7.
17 Bergström M, Eriksson B, Oberg K. et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-ll-DOPA to carbon-ll-dopamine. J Nucl Med 1996; 37: 32-7.
18 Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989; 26: 535-42.
19 Leenders KL, Palmer AJ, Quinn N. et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60.
20 Guttman M, Burns RS, Martin WRW. et al. PET studies of parkinsonian patients treated with autologous adrenal implants. Can J Neurol Sei 1989; 16: 305-9.
21 Huang SC, Yu DC, Bario JR. et al. Kinetics and modeling of L-6-[¹⁸F]fluoro-DOPA in human positron emission tomographic studies. J Cerebr Blood F Met 1991; 11: 898-913.
22 Reubi JC, Kvols LK, Waser B. et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 569-77.